Table of Contents Understanding Weight Loss Injections and Pancreatitis Risk Weight loss injections, primarily glucagon-like peptide-1 (GLP-1) receptor agonists , have become increasingly prescribed for obesity management in the UK
They decrease inflammatory markers, lower LDL cholesterol and triglycerides, and have been shown to reduce major adverse cardiovascular events
Managing Nausea/Malnutrition/Dehydration GLP1-RA medications such as Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro), etc
What is still unknown is how many people who cycle off GLP-1 drugs ultimately end up returning to their pre-GLP-1 lifestyle and eating habits
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial [press release]